Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAYFINDER: Tezepelumab to reduce oral corticosteroid use in adults with severe OCS-dependent asthma
2021-005457-85Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tezepelumab in severe asthma and asthma, sponsored by AstraZeneca. Primary endpoints: Proportion of participants who discontinued OCS without loss of asthma control at Week 28 and Proportion of participants who discontinued OCS without loss of asthma control at Week 52. Started Mar 2022; status: completed.
02
Drugs
03
Conditions
severe asthmaasthma
Beyond the preview
Go deeper on 2021-005457-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005457-85.